Seong-Yeon Bae received her Ph. D. degree in Pharmaceutical Sciences from Ewha Womans University in Seoul, Korea in 2016. During her Ph. D. studies, she focused on the biological functions of TPT1 (tumor protein, translationally-controlled 1) in tumorigenesis. She found that TPT1 activates both mTORC1 and mTORC2 signaling and thereby modulates EMT and autophagy. In our laboratory, her primary research interest is illuminating the mechanisms underpinning latent metastatic relapses which are the major clinical issues in breast cancer. Leveraging a powerful in vivo forward genetic screening platform, she performed very large, genome-wide CRISPR-Cas9 screenings to identify single genetic entities which govern dormancy and metastatic reactivation. Among potential dormancy enforcers, she is currently focusing on the Mediator Complex subunit 4 (Med4), and its effect on alteration in the epigenetic/transcriptional landscape and activation of integrin-mediated mechano-transduction. She is expecting her study to contribute to predicting high-risk patient subset for metastatic relapse and proposing the new adjuvant chemotherapy regimens to improve breast cancer patient’s life expectancy and quality of life.